Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma

Andrea B. Apolo, MD
Published Online: Thursday, Feb 16, 2017



Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

In this study, the combinations of cabozantinib/nivolumab and cabozantinib/nivolumab/ipilimumab were evaluated for safety and clinical activity. Both combinations were well tolerated and responses were seen at all dose levels, with the recommended doses at Cabo40/Nivo3 and Cabo40/Nivo3/Ipi1 (can you please spell these out? I’m not 100% sure if it’s 40 mg cabozantinib/3 mg nivolumab and 40 mg cabozantinib/3 mg nivolumab/1 mg ipilimumab)

In addition to responses in patients with mUC, rare tumors such as basaloid squamous cell carcinoma, urachal, and penile cancer also showed significant responses.
 

<<< View more from the 2017 Genitourinary Cancers Symposium



Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

In this study, the combinations of cabozantinib/nivolumab and cabozantinib/nivolumab/ipilimumab were evaluated for safety and clinical activity. Both combinations were well tolerated and responses were seen at all dose levels, with the recommended doses at Cabo40/Nivo3 and Cabo40/Nivo3/Ipi1 (can you please spell these out? I’m not 100% sure if it’s 40 mg cabozantinib/3 mg nivolumab and 40 mg cabozantinib/3 mg nivolumab/1 mg ipilimumab)

In addition to responses in patients with mUC, rare tumors such as basaloid squamous cell carcinoma, urachal, and penile cancer also showed significant responses.
 

<<< View more from the 2017 Genitourinary Cancers Symposium


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Updates from Singapore: Advances in Personalized Lung Cancer TreatmentFeb 28, 20171.5
Community Practice Connections™: 10th Annual New York Lung Cancer Symposium®Feb 28, 20173.0
Publication Bottom Border
Border Publication